-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 25, Kelun Pharmaceutical issued an announcement stating that its subsidiary Kelun Botai had reached a regional authorization cooperation agreement with Ellipses Pharma LTD in the United Kingdom.
A400 R & D project is the Cologne Great proprietary small molecule selective targeting RET kinase inhibitor formulation, the project was completed in March 2021 formally submitted an IND to the NMPA, layout and has a number of international patents.
Preparation, the project has formally submitted an IND application to NMPA in March 2021, and has laid out a number of international patents.
Preclinical studies have shown that a good in vivo A400 kinase inhibitory activity and selectivity; animal blood / brain bursts having advantages in the amount of dew and the like; a variety of clinical resistance mutations have been reported clinically effective.
A400 has the potential to overcome clinical drug-resistant mutations and improve the clinical efficacy of brain metastases.